Pharmafile Logo

Kraeber (UK) Ltd

The family owned business, Kraeber & Co GmbH, is an independent, technology based enterprise which was founded on the 1st January 1980 in Hamburg. Hanseatic tradition together with courageous entrepreneurship characterize our company. We are committed to open and global competition which we stand up with our service capabilities. Our emphasis is the development, production, marketing and sales of active pharmaceutical ingredients (APIs) of the highest purity. Kraeber has evolved into a niche marketer and supplier. By continously innovating productions, we became the quality market leader in Europe and in other parts of the world for many of our products.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

16 The Street, Saxon Street, Newmarket, Suffolk, CB8 9RU, United Kingdom
+44 (0)1638 731 297

 Latest Content from PMHub 

OPEN Health supports Genetic Alliance UK’s Rare Film Festival!

OPEN Health joined a number of rare disease patients, patient groups and industry representatives at the Regent Street cinema in London to see the winners announced at the Rare Film...

This isn’t goodbye, it’s see you in August!

Bedrock Group imagines, creates and delivers industry-leading benefits

Onyx Health receive national recognition as a “one to watch” business in Newcastle

Press Releases | February 10, 2020 | Onyx Health

Specialist marketing communications agency Onyx Health have been nationally recognised by The Sunday Times as one of six “one to watch” businesses based in Newcastle.

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Press Releases | February 3, 2020 | Onyx Health

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Empowering and equipping medical affairs teams to embrace an ever-expanding remit

Written by Jess Ingram and Francisca Costa, OPEN Health

Rethinking Electronic Medical Records

EMR systems are far from perfect. Clinician and PhD candidate Dr. Pao takes us through his perspective on the system and how he aims to lead the way by solving...